tesamorelin + CJC-1295 + ipamorelin vs cjc+ipa blend

tesamorelin + CJC-1295 + ipamorelin (F-tier) vs cjc+ipa blend (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

tesamorelin + CJC-1295 + ipamorelin — tier F

a three-peptide GH-axis blend with no located direct study, whose CJC variant, component forms, and ratio must be known before even its duration can be described.

three characterized component mechanisms do not create a characterized product. until the CJC variant, tesamorelin formulation, ipamorelin form, and per-vial ratio are verified, the blend's PK and outcome claims stay blocked.

0 located fixed-blend studies · half-life blend unknown; 5.8 to 8.1 days belongs only to confirmed CJC-1295 with DAC · growth hormone

cjc+ipa blend — tier A

clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.

the most common peptide-clinic GH-axis stack. CJC-1295 + ipamorelin amplifies pulse amplitude through two separate receptors.

PCAC '24 503A excluded · half-life CJC-1295: 30 min (no DAC); ipamorelin: ~2 h · growth hormone

at a glance

• tesamorelin + CJC-1295 + ipamorelin: tier F · 0 located fixed-blend studies
• cjc+ipa blend: tier A · PCAC '24 503A excluded

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.